Atorvastatin
HMG-CoA reductase inhibitor for lipid lowering and cardiovascular prevention
Atorvastatin is a synthetic HMG-CoA reductase inhibitor (statin) introduced by Pfizer in 1996 under the trade name Lipitor, which rapidly became the world's best-selling drug. Atorvastatin is one of the most potent statins and lowers LDL cholesterol significantly more effectively than older representatives of this class such as simvastatin or pravastatin. It is an essential component of cardiovascular primary and secondary prevention.
Atorvastatin is now widely available as a generic and serves as the reference substance when selecting a statin for patients with high cardiovascular risk. Large clinical trials including ASCOT-LLA, TNT, CARDS, and IDEAL have comprehensively documented its efficacy in reducing cardiovascular events.
Mechanism of Action
Atorvastatin competitively and reversibly inhibits the enzyme HMG-CoA reductase, which catalyses the rate-limiting step in cholesterol biosynthesis (mevalonate pathway). By inhibiting this enzyme, intracellular cholesterol synthesis in hepatocytes is reduced. In response, liver cells express more LDL receptors on their surface to meet cholesterol requirements through increased uptake from the blood.
This compensatory increase in LDL receptor density leads to a marked reduction in circulating LDL cholesterol (typically 40 to 55 percent depending on dose). At the same time, triglyceride-rich lipoproteins (VLDL, IDL) and remnant particles decrease, while HDL cholesterol rises modestly. Atorvastatin also has so-called pleiotropic effects: stabilisation of atherosclerotic plaques, improvement of endothelial function, reduction of inflammatory markers (hsCRP), and antiproliferative effects on smooth muscle cells.
Compared with other statins, atorvastatin has a long half-life (14 hours) and can therefore be taken at any time of day, which favours adherence.
Indications
- Primary prevention: Patients with elevated cardiovascular risk (diabetes mellitus, arterial hypertension, smoking, family history) and elevated LDL or total cholesterol
- Secondary prevention: After myocardial infarction, stroke, peripheral arterial occlusive disease, coronary revascularisation — regardless of baseline cholesterol
- Familial hypercholesterolaemia: Heterozygous (standard therapy) and homozygous (in combination with other measures)
- Mixed dyslipidaemia: Combined elevation of cholesterol and triglycerides
- Diabetes mellitus (type 1 and 2): With cardiovascular risk according to guidelines
Dosage and Administration
Standard dose: 10 mg once daily as starting dose. Titration: Increase to 20 mg, 40 mg, or maximum 80 mg daily depending on LDL target and tolerability; dose adjustment possible every 4 weeks. High-dose therapy (40 to 80 mg): For patients with very high risk (ACS, multivessel disease) or very high baseline LDL.
Atorvastatin can be taken independently of meals at any time of day. Unlike simvastatin or lovastatin, which should be taken in the evening due to their short half-lives (cholesterol is preferentially synthesised at night), atorvastatin offers flexibility due to its longer half-life. No dose adjustment is required in renal insufficiency; atorvastatin is contraindicated in severe hepatic insufficiency.
Side Effects
Common (1 to 10 percent): Myalgia (muscle pain without enzyme elevation), nasopharyngitis, joint pain, insomnia, nausea, diarrhoea, constipation, flatulence, headache.
Occasional to rare: Elevation of liver enzymes (ALT, AST) — discontinue if more than 3-fold elevation of the upper limit; myopathy with CK elevation; very rarely rhabdomyolysis (life-threatening muscle breakdown with renal failure, especially in combination with fibrates or high cyclosporine levels); hepatitis; peripheral neuropathy; interstitial lung disease.
Diabetes risk: Statins moderately increase the risk of newly developing type 2 diabetes mellitus (approximately 10 to 12 percent relative risk). This effect is dose-dependent and must be evaluated in relation to cardiovascular benefit; in high-risk patients the benefit clearly outweighs the risk.
Interactions
- Strong CYP3A4 inhibitors (clarithromycin, erythromycin, itraconazole, ketoconazole, HIV protease inhibitors): Marked increase in atorvastatin plasma levels; myopathy risk increases considerably; dose reduction or temporary discontinuation required
- Ciclosporin: Strong increase in atorvastatin exposure; maximum daily dose 10 mg with concurrent use
- Fibrates (gemfibrozil, fenofibrate): Combined myopathy risk; gemfibrozil increases statin levels via OATP transporter inhibition; avoid combination if possible
- Grapefruit juice: Inhibits intestinal CYP3A4; increased atorvastatin absorption; avoid large quantities
- Rifampicin: CYP3A4 induction; markedly reduced atorvastatin efficacy
- Digoxin: Atorvastatin can slightly increase digoxin levels; monitoring advisable
Special Notes
Liver enzyme monitoring: Determine liver values before starting therapy; recheck if symptoms of hepatic dysfunction occur. Routine repeated determination is not mandatory according to current guidelines in the absence of symptoms.
Monitor for muscle pain: Patients should watch for unexplained muscle pain, muscle weakness, or dark-coloured urine and seek medical advice promptly if these signs occur. If symptoms are severe, atorvastatin should be paused until CK is measured.
Pregnancy and breastfeeding: Atorvastatin is contraindicated in pregnancy and breastfeeding. Cholesterol is essential for foetal development. Women of childbearing age must use reliable contraception.
LDL target values: According to ESC/EAS guidelines 2019, LDL targets for very high cardiovascular risk are below 1.4 mmol/l (54 mg/dl) and at least 50 percent reduction from baseline. Atorvastatin 40 to 80 mg is the preferred statin when these targets are pursued with a statin alone.
Related Topics
- Simvastatin — Older statin, frequently prescribed as generic
- Rosuvastatin — Potent statin without CYP3A4 metabolism
- Ezetimibe — Cholesterol absorption inhibitor, often combined with statins
- All active ingredients overview
Frequently Asked Questions
Does atorvastatin need to be taken in the evening?
No. Unlike simvastatin and lovastatin, atorvastatin can be taken at any time of day owing to its long half-life of approximately 14 hours. Consistent daily intake at the same time is more important than the specific time of day.
How long does it take for atorvastatin to lower cholesterol?
A significant LDL reduction is measurable after 2 to 4 weeks of therapy. Maximum effect is reached after approximately 4 weeks. A laboratory check after 4 to 6 weeks to assess efficacy and tolerability is advisable.
Can I drink grapefruit juice while taking atorvastatin?
Grapefruit juice inhibits the enzyme CYP3A4 in the gut and can thereby increase the absorption of atorvastatin. In moderate amounts (one glass daily) the risk is low; however, consumption of large amounts of grapefruit juice should be avoided, especially at higher atorvastatin doses.